Chang CF, Lai JH, Wu JC, Greig NH, Becker RE, Luo Y, Chen YH, Kang SJ, Chiang YH, Chen KY (2017) <br />(-)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury<br /><i>Brain Research</i> <b>1677</b>: 118<br /><br />Tweedie D, Fukui K, Li Y, Yu QS, Barak S, Tamargo IA, Rubovitch V, Holloway HW, Lehrmann E, Wood WH, 3rd, Zhang Y, Becker KG, Perez E, Van Praag H, Luo Y, Hoffer BJ, Becker RE, Pick CG, Greig NH (2016) <br />Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms<br /><i>PLoS ONE</i> <b>11</b>: e0156493<br /><br />Giacobini E, Becker RE (2007) <br />One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?<br /><i>J Alzheimers Dis</i> <b>12</b>: 37<br /><br />Becker RE (2006) <br />Treating Alzheimer's disease: do clinical trial methods produce unnecessary practitioner dilemmas?<br /><i>Am J Alzheimers Dis Other Demen</i> <b>21</b>: 81<br /><br />Moriearty PL, Seubert P, Galasko D, Markwell S, Unni L, Vicari S, Becker RE (1999) <br />Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease<br /><i>Methods Find Exp Clin Pharmacol</i> <b>21</b>: 549<br /><br />Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S (1998) <br />Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study<br /><i>lzheimer Disease & Associated Disorders</i> <b>12</b>: 54<br /><br />Kronforst-Collins MA, Moriearty PL, Ralph M, Becker RE, Schmidt B, Thompson LT, Disterhoft JF (1997) <br />Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits<br /><i>Pharmacology, Biochemistry & Behavior</i> <b>56</b>: 103<br /><br />Bartels CF, Moriearty PL, Becker RE, Mountjoy CP, Lockridge O (1995) <br />Acetylcholinesterase Gene Sequence and Copy Number are Normal in Alzheimer's Disease Patients Treated with the Organophosphate Metrifonate<br /><i>In Enzyme of the Cholinesterase Family - Proceedings of Fifth International Meeting on Cholinesterases</i> <b>(Quinn, D.M., Balasubramanian, A.S., Doctor, B.P., Taylor, P., Eds) Plenum Publishing Corp.</b>: 479<br /><br />Unni LK, Womack C, Hannant ME, Becker RE (1994) <br />Pharmacokinetics and pharmacodynamics of metrifonate in humans<br /><i>Methods Find Exp Clin Pharmacol</i> <b>16</b>: 285<br /><br />Unni LK, Radcliffe J, Latham G, Sunderland T, Martinez R, Potter W, Becker RE (1994) <br />Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study<br /><i>Methods Find Exp Clin Pharmacol</i> <b>16</b>: 373<br /><br />Moriearty PL, Thornton SL, Becker RE (1993) <br />Transdermal patch delivery of acetylcholinesterase inhibitors<br /><i>Methods Find Exp Clin Pharmacol</i> <b>15</b>: 407<br /><br />Moriearty PL, Becker RE (1992) <br />Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL)<br /><i>Methods Find Exp Clin Pharmacol</i> <b>14</b>: 615<br /><br />Unni LK, Hutt V, Imbimbo BP, Becker RE (1991) <br />Kinetics of cholinesterase inhibition by eptastigmine in man [letter]<br /><i>European Journal of Clinical Pharmacology</i> <b>41</b>: 83<br /><br />Kumar V, Becker RE (1989) <br />Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease<br /><i>Int J Clinical Pharmacology & Therapeutics Toxicol</i> <b>27</b>: 478<br /><br />